Not sure how to read the table with modified to treat and intent to treat. Seems to me the per protocol arm is most relevant. First of its kind drug with response rates higher than the last line of defense antibiotic is incredible. I would like to understand why the medium dose response dips down compared to the low and high dose.
Please remember the chance of antibiotic resistance is not likely with 30063. My initial thoughts.
It seems to me that the medium dose arm used a much smaller initial dose. That might be the key: one large dose may be sufficient for most patients.
I can't find the dosage link on Poly's website.
The same thing stood out to me also. Maybe just due to small sample size and will even out with larger trial? The good low-dose numbers are what matter most though in my opinion.
I'm slightly disappointed at the overall efficiency VS Daptomycin - I was hoping for a bigger spread. *But the short regimen is Big in my opinion, and is what will make this drug the preferred treatment for mrsa. The press release mentions that a single-dose arm may be included in the next trial (wow).
Also, lets remember that this drug will be used for other indications besides mrsa, including cancer therapy and blood stream infections. I see blockbuster potential.
What is interesting is they only displayed the results of 63 at 3 days versus dapto at 3 days. Rather than dapto at 7 days which is the fair comparison since that is what dapto needs to be effective. Could be hiding that dapto did better than 75%. Or it could just be that they saw it as being more fair to compare at the same day endpoint. Anyway, I guess we'll have to wait until 9!